Förpackning om 10 vialer6 i lagerSpara 25 %Retatrutide 30 mg
Tri-agonist GLP-1 / GIP / glukagon-forskningspeptid
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Enbart för forskningsbruk. Denna förening säljs strikt för in vitro-forskning och laboratorieändamål och är inte avsedd för mänsklig konsumtion eller terapeutisk användning. Genom att köpa bekräftar du att du är en kvalificerad forskare och godkänner vår fullständiga ansvarsfriskrivning.
Endast 6 förpackningar kvar
Trippelreceptoragonist-forskningspeptid studerad för kombinerade effekter på GLP-1-, GIP- och glukagonsignaleringsvägar i metaboliska forskningsapplikationer.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mekanism
Studerad för simultan agonism av GLP-1-, GIP- och glukagonreceptorer. Forskning kopplad till markörer för metabol hastighet, mättnad och energiförbrukning i studiepopulationer.
HPLC-verifierad mot en renhetsspecifikation på ≥99 %. Oberoende testad av ackrediterade tredjepartslaboratorier.
Retatrutide — vanliga frågor
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Guider relaterade till Retatrutide
Forskare utforskar också
Förpackning om 10 vialerSpara 22 %MOTS-c
Lyofiliserat pulver10 mg · 2 strengths
Mitokondriellt härledd metabol peptid
I 2 stackar
Förpackning om 10 vialerSpara 17 %5-Amino-1MQ
Lyofiliserat pulver50 mg · 3 strengths
NNMT-inhibitor, forskningsförening
Förpackning om 10 vialerSpara 15 %L-Carnitine
Sterile solution10 ml × 600 mg/ml
Mitokondriell fettsyratransportör
I 1 stack